Singapore eDevelopment Limited (the “Company” and together with its subsidiaries, the “Group”) wishes to announce that the Company’s wholly-owned subsidiary, SeD Home, Inc., has incorporated a wholly-owned subsidiary, with details as follows:-
Name of subsidiary : SeD Home Reit Inc. (“SeD Home Reits”)
Place of Incorporation : Maryland, United States of America
Date of Incorporation : 20 August 2019
Issued and Paid-up Capital : 1,000 shares
2. PRINCIPAL ACTIVITIES
SeD Home Reits will provide integrated services consisting of land development, home building, home sale, property management and home investment. It intends to engage with strategic partners to do home building and development, capitalising on its land banks in Ballenger Run, Maryland and Black Oak, Houston. In addition, it will concurrently acquire other properties within the United States of America for rental returns. As at the date of this announcement, SeD Home Reits is a dormant company.
3. DIVIDEND INCOME FOR SED HOME REITS SHARES
SeD Home Reits targets to pay dividend of up to 8% annualized yield on a semi-annual basis when it is generating income and profitable.
4. FINANCIAL EFFECTS OF THE INCORPORATION
The incorporation of SeD Home Reit Inc. is funded through internal resources and is not expected to have any material impact on the net tangible assets per share and the earnings per share of the Company for the current financial year ending 31 December 2019.
5. INTERESTS OF DIRECTORS AND CONTROLLING SHAREHOLDERS
None of the Directors or Controlling Shareholders (as defined in the Listing Manual) of the Company has any interest, direct or indirect, in the incorporation of SeD Home Reit Inc. (other than through their respective shareholdings in the Company, if any).
BY ORDER OF THE BOARD
Chan Heng Fai
Executive Chairman and Chief Executive Officer
Todos Medical Signs Binding Term Sheet with HWH World), a wholly-owned subsidiary of Singapore eDevelopment (SGX:40V) for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
September 13, 2019 07:30 ET | Source: Todos Medical Ltd.
REHOVOT, Israel and SINGAPORE, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, today announced it has entered into a binding term sheet with HWH World Pte Ltd. (“HWH World”), a wholly-owned subsidiary of Singapore eDevelopment (SGX:40V) for the grant of exclusive marketing rights for Todos Medical’s TM-B1 and TM-B2 tests to HWH World’s network of members in Singapore, Malaysia, the Philippines, Vietnam, Thailand, Indonesia, South Korea, Hong Kong, China, the United States and Canada. HWH World is a marketing firm that focuses on health and wellness. HWH World will work closely with Todos Medical to achieve regulatory approval in Singapore, where Todos Medical recently completed clinical studies, and thereafter expand into other markets. Todos remains free to partner with other companies to market and distribute its diagnostic tests through traditional means, including direct to consumer, through physicians, hospitals and/or government health systems.
“Todos Medical’s innovative artificial intelligence-based blood testing technology has shown strong results for breast cancer screening and diagnosis in Singapore,” said Heng Fai Chan, Chairman of HWH World. “This represents a tremendous opportunity for HWH World members to take control of their healthcare by getting better information about potential cancer to ensure they are seeking treatment early in the disease progression. This will improve the well-being of our female members and help differentiate us from other wellness programs in the market. Many Asian women are forced to have unnecessary breast biopsies because mammograms are not very effective in this population. Todos has identified a solution to this problem, and HWH World is looking forward to bringing the TM-B1 and TM-B2 tests to our members both in Asia and as we expand into North America.”
“Having just completed a substantial clinical study in Singapore that demonstrated the superiority of our assay versus mammography in prospectively classifying cancer and non-cancer subjects, especially among those with inconclusive mammogram results (BI-RADS III/IV), we are pleased to secure our first Asian partner in HWH World. Our two companies are aligned in viewing the significant value by utilizing a blood test that will determine whether a biopsy is necessary in breast cancer,” said Herman Weiss, M.D., President and CEO of Todos Medical.
About Todos Medical Ltd.
Todos Medical Ltd. is a cancer in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos Medical has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test®, a blood test for diagnosing Alzheimer’s disease.
For more information, the content of which is not part of this press release, please visit
About Breakthrough Diagnostics, Inc.
Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (19.99%). Breakthrough has been assigned the intellectual property and other rights to the LymPro Test®, a diagnostic blood test for Alzheimer’s disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical has provided Amarantus with notice of Todos’ decision to exercise its exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.
The Lymphocyte Proliferation Test (LymPro Test™) determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as surrogates for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain
Singapore to Set World’s First Ad Ban for High Sugar Drinks
By Alfred Cang
Singapore, one of Asia’s biggest per capita consumers of sugar, plans to implement a total ban on ads for packaged drinks with very high sugar content in an attempt to reduce illnesses in the rapidly-aging city state.
Such drinks as well as medium-to-high sugar content beverages must also carry a label on the front of the pack to signal that it’s unhealthy, Senior Minister of State for Health Edwin Tong told a conference Thursday. The city state will be the first country in the world to implement a ban on ads for very high sugar drinks, according to a Straits Times report.
“Our rapidly aging population and rising prevalence of chronic diseases will lead us to an unsustainable, costly system with poorer health outcomes if we do not intervene,” Tong said, according to a transcript. The number of Singaporeans aged 65 and over will double in the next 10 years, he said.
Southeastern Asian countries including Singapore and Malaysia are among the world’s top consumers of sugar on a per capita basis, according to Bloomberg Intelligence. That’s led to an increase in health issues, with diabetes and obesity among top diseases, similar to other developed economies.
Consumers globally are cutting back on the sweetener with food companies committing to reducing sugar and calorie content, Pablo Sherwell, head of food and agribusiness research for North America at Rabobank, said last month. These initiatives could accelerate a slowdown in consumption, Sherwell said.
For Singapore, the government had asked for feedback on the possibility of introducing an excise duty or a tax on manufacturers and importers, as well as an outright ban on the sale of high-sugar beverages, said Tong, calling the move a “the War on Diabetes.”